What is Nicotinamide Riboside (NR)?
Nicotinamide riboside is a vitamin B3-related NAD+ precursor distinct from NMN and direct NAD+.[1][2][3]
The oral and injectable routes use separate evidence: controlled oral trials support daily capsules, while the vial schedule remains investigational and product-specific.[1][2][3]
What Nicotinamide Riboside (NR) is investigated for
Nicotinamide Riboside (NR) evidence is grouped by practical use case and oral, injectable, and topical route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.
Oral NAD+ biomarker support
Oral
Oral NAD+ biomarker support
Oral
Oral NAD+ biomarker restoration is the most reproducible NR finding; it should not be treated as proof of symptom, disease, or longevity benefit.[1][12][13]
Walking performance in peripheral artery disease
Oral
Walking performance in peripheral artery disease
Oral
The walking signal is promising but condition-specific and needs larger independent confirmation before routine clinical claims.[7][13]
Human evidence
The NICE randomized clinical trial in peripheral artery disease reported a modest improvement in six-minute walk distance after six months, with a stronger exploratory signal in a combination arm.[7]
Neurocognitive support
Oral
Neurocognitive support
Oral
NR is an active research strategy for neurologic conditions, not an established cognitive enhancer or neurodegenerative treatment.[5][6][23]
Cardiometabolic health
Oral
Cardiometabolic health
Oral
Cardiometabolic use remains exploratory and should not be represented as a proven glucose, lipid, blood-pressure, or weight-loss intervention.[18][15][14]
Evidence snapshot
Overall confidence
NR has controlled oral human data and early injectable research.[1][2][3][28][32]
Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.
Human evidence
Human data are strongest for oral NR; injection evidence is early and protocol-focused.[1][2][3][28]
Animal / preclinical
The approved defaults rely on route-matched human or protocol sources rather than animal dose extrapolation.[1][2][3]
Mechanism support
NR enters NAD+ biosynthesis through nicotinamide riboside kinase pathways.[1][2][3]
Forms & administration
NR has oral supplement and NR-chloride vial presentations. Topical gels remain experimental, with animal-only evidence. Each form has distinct concentration and delivery requirements; topical preparations cannot inherit the amounts, absorption or treatment expectations associated with oral supplements or injectable products.[1][2][3][28][32][31]
Dosing & protocols
These ranges are general reference points, not personal dosing instructions.
Typical Range
Oral protocols commonly use 300 mg per day. Injectable research protocols use 50 mg per dose.[1][2][3][28][32]
Frequency
Oral NR is taken once daily. Injection schedules use daily doses for 3 days, then 3 doses weekly.[1][28]
Timing Considerations
Cycle Length
Oral protocols may run 8 weeks. Injectable research schedules may continue to day 100.[1][28]
What to expect
First 1–2 weeks
Blood NAD+ and related metabolites can rise early, but a biomarker response does not predict a noticeable clinical effect.[19][1]
Weeks 4–8
Most short trials reassess NAD+ biomarkers, tolerability, and condition-specific exploratory outcomes in this window; many metabolic and cognitive outcomes remain unchanged.[1][5][6]
Months 3–6
Longer condition-specific trials may be needed for functional outcomes; the PAD walking signal was measured over six months and should not be generalized to healthy users.[7]
After stopping
NAD-related biomarker gains are not expected to represent a permanent change, but exact washout timing and symptom durability are not consistently mapped across trials.[2][12]
Safety profile
Oral NR has controlled human tolerability data across several short trials, including a high-dose Parkinson's safety study, without a consistent excess pattern of serious adverse events. Long-term and injectable safety remain less certain.[1][2][4][33]
Who Nicotinamide Riboside (NR) is not for
Route-specific avoid and medical-review notes:
Regulatory status
United States
Nicotinamide Riboside (NR) is not FDA-approved as a drug for the reviewed routes. Compounded, supplement, and research-market availability are separate from FDA approval.[33][29]
| Route | FDA drug approval | 503A compounding |
|---|---|---|
| Oral | Not Approved Nicotinamide Riboside (NR) is not FDA-approved as a oral drug for the reviewed use. Compounded, supplement, or research availability is separate from FDA approval.[33] | Not Listed Nicotinamide Riboside (NR) does not have FDA-approved oral dosing for the reviewed use; any compounded preparation remains product- and prescriber-specific.[33] |
| Injectable | Not Approved Nicotinamide Riboside (NR) is not FDA-approved as a injectable drug for the reviewed use. Compounded, supplement, or research availability is separate from FDA approval.[33] | Not Listed Nicotinamide Riboside (NR) does not have FDA-approved injectable dosing for the reviewed use; any compounded preparation remains product- and prescriber-specific.[33] |
Oral
FDA drug approval
Not ApprovedNicotinamide Riboside (NR) is not FDA-approved as a oral drug for the reviewed use. Compounded, supplement, or research availability is separate from FDA approval.[33]
503A compounding
Not ListedNicotinamide Riboside (NR) does not have FDA-approved oral dosing for the reviewed use; any compounded preparation remains product- and prescriber-specific.[33]
Injectable
FDA drug approval
Not ApprovedNicotinamide Riboside (NR) is not FDA-approved as a injectable drug for the reviewed use. Compounded, supplement, or research availability is separate from FDA approval.[33]
503A compounding
Not ListedNicotinamide Riboside (NR) does not have FDA-approved injectable dosing for the reviewed use; any compounded preparation remains product- and prescriber-specific.[33]
International
Nicotinamide riboside chloride is authorized for specified uses and conditions in the European Union novel-food framework; authorization is ingredient- and condition-specific, not drug approval.[30]
Sports & competition
Tested athletes should obtain sport-specific review for non-approved NAD-pathway products.[35]
How it works
Oral NR is absorbed and metabolized through pathways that can raise circulating NAD-related metabolites. Controlled studies demonstrate biomarker changes across several daily doses.[1][2][3]
Injectable NR chloride bypasses oral delivery but remains an investigational route. Its preparation and cadence come from a specific human safety protocol rather than from direct NAD+ practice.[1][2][3][28]
Research gaps & open questions
What the current literature has not yet settled about Nicotinamide Riboside (NR):
Injectable NR needs larger placebo-controlled studies that measure safety, blood levels, tissue exposure, and clinical outcomes.[1][2][3]
Long-term clinical outcomes need independent testing that goes beyond changes in NAD-related blood biomarkers.[1][2][3]
The peripheral-artery-disease walking signal needs larger replication and clarity on which patients, co-interventions, and outcomes are most responsive.[7][13]
Neurologic trials need clearly chosen clinical outcomes and enough duration to distinguish biomarker movement from cognitive or disease-modifying benefit.[5][6][23]
Research should define long-term safety and clinically meaningful outcomes in older adults, chronic-disease populations, and people taking multiple medications.[12][13]
Common questions
Is NR direct NAD+?
Why does the vial use NR chloride as the medication name?
Does NR have proven anti-aging or longevity benefits?
Does NR improve memory or treat neurodegenerative disease?
Myths & misconceptions
Myth
An NR vial is a generic NAD+ vial.
Myth
A higher blood NAD+ result proves that NR is improving health.
Myth
Food or supplement availability means NR is an FDA-approved drug.
History & discovery
Nicotinamide riboside is a vitamin B3 form and NAD+ precursor. Human development progressed from oral bioavailability and pharmacokinetic studies to randomized trials across healthy aging, metabolic, neurologic, vascular, and mobility contexts. Across that history, NAD+ biomarker engagement has been more reproducible than clinical benefit.[27][19][12][13]
NR was contextualized alongside nicotinic acid and nicotinamide as a human NAD+ precursor vitamin.[27]
Human studies established oral bioavailability, blood NAD+ increases, and short-term tolerability across controlled exposure ranges.[25][2][1]
Trials expanded into neurologic, vascular, pulmonary, muscle, and mobility outcomes, with mixed clinical results despite biomarker engagement.[20][7][21][23]
35 citations
Show citationsHide citations
- [1]Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight AdultsScientific Reports, 2019. human clinical.
- [2]Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adultsNature Communications, 2018. human clinical.
- [3]Acute nicotinamide riboside supplementation increases human cerebral NAD+ levels in vivoAging Cell, 2024. human clinical.
- [4]NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's diseaseNature Communications, 2023. human clinical.
- [5]A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairmentGeroScience, 2024. human clinical.
- [6]Cognitive and Alzheimer's disease biomarker effects of oral nicotinamide riboside supplementation in older adults with subjective cognitive decline and mild cognitive impairmentAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2025. human clinical.
- [7]Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trialNature Communications, 2024. human clinical.
- [8]Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal originAging Cell, 2023. human clinical.
- [9]Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double-Blind Randomized Crossover Placebo-Controlled TrialAging Cell, 2025. human clinical.
- [10]The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humansNature Metabolism, 2026. human clinical.
- [11]The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-AnalysisJournal of Cachexia, Sarcopenia and Muscle, 2025. review.
- [12]What is really known about the effects of nicotinamide riboside supplementation in humansScience Advances, 2023. review.
- [13]NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidenceAgeing Research Reviews, 2026. review.
- [14]Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humansAmerican Journal of Clinical Nutrition, 2020. human clinical.
- [15]Nicotinamide riboside does not alter mitochondrial respiration, content or morphology in skeletal muscle from obese and insulin-resistant menThe Journal of Physiology, 2020. human clinical.
- [16]Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With ObesityJournal of Clinical Endocrinology & Metabolism, 2019. human clinical.
- [17]Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory SignaturesCell Reports, 2019. human clinical.
- [18]A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effectsAmerican Journal of Clinical Nutrition, 2018. human clinical.
- [19]An open-label, non-randomized study of the pharmacokinetics of nicotinamide riboside and its effects on blood NAD+ levels in healthy volunteersPLOS ONE, 2017. human clinical.
- [20]The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's diseaseCell Metabolism, 2022. human clinical.
- [21]Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trialNature Aging, 2024. human clinical.
- [22]Nicotinamide riboside combined with exercise to treat hypertension in middle-aged and older adults: a pilot randomized clinical trialGeroScience, 2025. human clinical.
- [23]A phase-II randomized controlled pilot study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairmentAlzheimer's & Dementia, 2026. human clinical.
- [24]Safety assessment of nicotinamide riboside, a form of vitamin B3Human & Experimental Toxicology, 2016. animal.
- [25]Nicotinamide riboside is uniquely and orally bioavailable in mice and humansNature Communications, 2016. human clinical.
- [26]Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotectionCurrent Opinion in Clinical Nutrition and Metabolic Care, 2013. review.
- [27]Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutritionAnnual Review of Nutrition, 2008. review.
- [28]Randomized, Open-label, Safety Study of Subcutaneous and Intramuscular Injections of Niagen PlusClinicalTrials.gov, 2025. clinical trial registry.
- [29]Agency Response Letter GRAS Notice No. GRN 000635U.S. Food and Drug Administration, 2016. regulatory.
- [30]Union list of novel foodsEuropean Commission. regulatory.
- [31]Boosting wound healing in diabetic rats: The role of nicotinamide riboside and resveratrol in UPR modulation and pyroptosis inhibition.International immunopharmacology, 2024 May 10. animal.
- [32]Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit OfferingNiagen Bioscience, 2026-05-04. reference catalog.
- [33]Compounding and the FDA: Questions and AnswersU.S. Food and Drug Administration. official guidance.
- [34]FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-RegulatedU.S. Food and Drug Administration. official guidance.
- [35]The 2026 List of Prohibited Substances and MethodsWorld Anti-Doping Agency, 2026. regulatory.


